Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - Boorjian, SA; Alemozaffar, M; Konety, BR (Lancet Oncol, 2021)
et al.